CRL · 10-Q · 2026Q2 · Full report

Acquisitions and Divestitures

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 71 · Surprise 60 · In source text

Charles River acquired an additional 79% equity interest in PathoQuest SAS on April 17, 2026 for $67.6 million, funding the transaction with cash and Credit Facility proceeds. On January 14, 2026, it acquired Cambodian NHP Supplier assets for a preliminary $507.3 million, including $335.0 million paid at closing and $172.3 million of deferred consideration, with $105.0 million still payable at June 27, 2026. On May 22, 2026, the company sold European Discovery Services businesses to IQVIA for $125.2 million in cash and recognized a $0.3 million gain. On May 6, 2026, it sold CDMO and Cell Solutions to GI Partners and recognized a $181.7 million six-month loss, while retaining potential funding obligations of up to $45.0 million and contingent payment rights of up to $50.0 million.

Key facts

• On May 22, 2026, Charles River sold certain European Discovery Services businesses to IQVIA for a preliminary purchase price of $125.2 million in cash, net of costs to sell and subject to customary closing adjustments. source
• On January 14, 2026, Charles River completed the acquisition of certain assets of K.F. Cambodia Ltd for a preliminary purchase price of $507.3 million consisting of $335.0 million paid at closing and $172.3 million acquisition-date fair value of deferred consideration. source
• Acquisition of businesses and assets, net of cash acquired for the six months ended June 27, 2026 was $(467,254) thousand, primarily driven by the acquisition of the Cambodian NHP Supplier and PathoQuest. source
• Charles River may earn up to $50.0 million of contingent payments from the CDMO and Cell Solutions sale, which have been valued at $15.7 million using a discounted probability weighted model. source
• On April 17, 2026, Charles River completed the acquisition of an additional 79% equity interest in PathoQuest SAS for $67.6 million. source
• In March 2026, Charles River sold assets at its Wilmington, Massachusetts site for cash consideration of $60.1 million, net of costs to sell. source
• Charles River may earn up to $10.0 million of contingent payments from the European Discovery Services sale, which have been valued at $2.8 million using a discounted probability weighted model. source
• On May 6, 2026, Charles River sold its CDMO and Cell Solutions businesses to GI Partners for net cash paid to the buyer of $12.4 million, net of costs to sell and subject to customary closing adjustments. source

Impact estimates